S6 Ep5: FDA Approval Insights: Brexucabtagene Autoleucel in Relapsed/Refractory B-ALL

OncLive® On Air
01/11/2021 14 min Temporada 6 Episodio 5
S6 Ep5: FDA Approval Insights: Brexucabtagene Autoleucel in Relapsed/Refractory B-ALL

Listen "S6 Ep5: FDA Approval Insights: Brexucabtagene Autoleucel in Relapsed/Refractory B-ALL"

Descargar episodio Ver en sitio original

Episode Synopsis

Dr. Shah discusses the FDA approval of brexucabtagene autoleucel in relapsed/refractory B-cell acute lymphoblastic leukemia, key findings from the pivotal ZUMA-3 trial, and next steps with CAR T-cell therapy in the field.

More episodes of the podcast OncLive® On Air

S14 Ep74: PRRT With 177Lu-Edotreotide Improves Outcomes vs Everolimus in Metastatic GEP-NETs: With Jonathan R. Strosberg, MD 07/01/2026
S14 Ep73: Experts Explore Intersections Between Breast Surgery and Radiation for Comprehensive Care: With Hirsch Matani, MD; Elizabeth Zhang-Velten, MD; and Valentina Bonev, MD, DABS, FACS, FSSO 05/01/2026
S14 Ep72: CLL Treatment Paradigm Shifts With Evolving Treatment Sequencing and BTK Inhibition: With Joanna M. Rhodes, MD, MSCE; and Krish Patel, MD 31/12/2025
S14 Ep71: FDA Approval of Enfortumab Vedotin/Pembrolizumab Redefines Perioperative Care for Cisplatin-Ineligible MIBC: With Christof Vulsteke, MD, PhD 31/12/2025
S14 Ep70: Osimertinib Carves a Continuing Role in Perioperative NSCLC Management: With Julia Rotow, MD; and Gavitt Woodard, MD 29/12/2025
S14 Ep69: MRI Techniques Evolve for Glioma Diagnosis, Response Assessment, and Surveillance: With Kathryn S. Nevel, MD; and Michael Veronesi, MD, PhD 25/12/2025
S14 Ep68: ctDNA Testing Opens Avenues for the Future of Breast Oncology: With Jason Mouabbi, MD 22/12/2025
S14 Ep67: Microbiome Profiling Highlights Impact of Butyrate Loss on Post-Transplant Outcomes in Multiple Myeloma: With Pooja M. Phull, MD 18/12/2025
S14 Ep66: Ongoing Sigvotatug Vedotin Exploration Highlights Potential for Biomarker Advancement in NSCLC: With Edward S. Kim, MD, MBA; and Jyoti Malhotra, MD, MPH 17/12/2025
S14 Ep65: ASH 2025 LBA BRUIN-CLL 313 Update: Pirtobrutinib vs Bendamustine/Rituximab in 1L CLL 17/12/2025
© 2003-2026 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA